Effects of fexofenadine hydrochloride in a guinea pig model of antigen-induced rhinitis

Pharmacology

Volumn 75, Issue 2, 2005, Pages 76-86

  Sakairi, Takashi ^a   Suzuki, Katsuhisa ^a   Makita, Shigeki ^a   Wajima, Teruaki ^a   Shakuto, Shuji ^a   Yoshida, Yasushi ^a   Yaguchi, Masafumi ^a  

^a SANOFI   (France)

Author keywords

Fexofenadine; Guinea pig; Histamine; Rhinitis; Thromboxane

Indexed keywords

FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPYRAMINE; OVALBUMIN; RAMATROBAN; TERFENADINE; THROMBOXANE; THROMBOXANE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GUINEA PIG; MALE; NONHUMAN; NOSE AIRWAY RESISTANCE; NOSE CAVITY; PRIORITY JOURNAL; RHINITIS; SENSITIZATION;

AIRWAY RESISTANCE; ANIMALS; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; CARBAZOLES; DISEASE MODELS, ANIMAL; GUINEA PIGS; LEUKOTRIENES; MALE; OVALBUMIN; PYRILAMINE; RHINITIS; SULFONAMIDES; TERFENADINE; THROMBOXANES; TOSYL COMPOUNDS;

EID: 24744468968     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087124     Document Type: Article

References (50)

1. Okuda M: Mechanism of onset of nasal allergy (in Japanese). Jpn J Allergol 1990;39:301-306.
2. Naclerio RM: Pathophysiology of perennial allergic rhinitis. Allergy 1997;52(suppl):7-13.
3. Baraniuk JN: Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997;99:S763-S772.
4. Ishikawa T: Nasal allergy - its immunological view (in Japanese). Arerugi 1999;48:1296-1305.
5. Howarth PH, Salagean M, Dokic D: Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55(suppl 64):7-16.
6. Narita S, Asakura K, Kataura A: Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol 1996;109:161-166.
7. Kaise T, Akamatsu Y, Ohmori K: Effect of oxatomide on experimental allergic rhinitis in guinea pigs. Jpn J Pharmacol 1998;76:223-226.
8. Nabe T, Mizutani N, Shimizu K, Takenaka H, Kohno S: Development of pollen-induced allergic rhinitis with early and late phase nasal blockage in guinea pigs. Inflamm Res 1998;47:369-374.
9. Fujita M, Yonetomi Y, Shimouchi K, Takeda H, Aze Y, Kawabata K, Ohno H: Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs. Eur J Pharmacol 1999;369:349-356.
10. Yamasaki M, Mizutani N, Sasaki K, Nabe T, Matsumoto T, Ashida Y, Kohno S: Involvement of thromboxane A2 and peptide leukotrienes in early and late phase nasal blockage in a guinea pig model of allergic rhinitis. Inflamm Res 2001;50:466-473.
11. Noguchi Y, Otsuki I, In I, Munehasu S, Ishiko J: The combined effect of tetrahydrozoline HCl and prednisolone in Cor-Tyzine® nasal solution (in Japanese; English abstract). Pharmacometrics 1980;20:935-940.
12. Fujita M, Yonetomi Y, Takeda H, Nakagawa N, Kawabata K, Ohno H: Effects of a specific cysteinyl leukotriene antagonist, pranlukast, on antigen-induced cysteinyl leukotriene-mediated rhinitis in guinea pigs. Jpn J Pharmacol. 1997;75:347-353.
13. Narita S, Asakura K, Shirasaki H, Kataura A: Effects of a cysteinyl leukotriene antagonist, ONO-1078 (pranlukast, on total airway resistance after antigen challenge in sensitized guinea pigs. Inflamm Res 1997;46:143-146.
14. Yamasaki M, Matsumoto T, Fukuda S, Nakayama T, Nagaya H, Ashida Y: Involvement of thromboxane A2 and histamine in experimental allergic rhinitis of guinea pigs. J Pharmacol Exp Ther 1997;280:1471-1479.
15. Yasui K, Asayama F, Furue Y, Arimura A: Involvement of thromboxane A2 in antigen-induced nasal blockage in guinea pigs. Allergy Immunol 1997;112:400-405.
16. Shizawa T, Maeda K, Abe K, Ishii T, Kamitani T: Effects of TMK688, a novel anti-allergic drug, on allergic nasal obstruction and exudative responses in sensitized guinea pigs. Naunyn-Schmiedeberg's Arch Pharmacol 1997;356:815-819.
17. Hironaka T, Sawada S, Yamada S, Miwa Y, Yashita T, Yamaguchi K, Kyuki K: Effect of a novel thromboxane A2 receptor antagonist, BAY u 3405, on experimental allergic rhinitis (in Japanese, English abstract). Jpn Pharmacol Ther 1996;24:1049-1055.
18. Yasui K, Asanuma F, Arimura A: Inhibitory effect of a TP-receptor antagonist, S-1452, on antigen-induced nasal plasma exudation in guinea pig model for allergic rhinitis. Pharmacology 2001;63:65-70.
19. Markham A, Wagstaff AJ: Fexofenadine. Drugs 1998;55:269-274.
20. Simpson K, Jarvis B: Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-321.
21. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-420.
22. Paolieri F, Battifora M, Riccio AM, Bertolini C, Cutolo M, Bloom M, Ciprandi G, Canonica GW, Bagnasco M: Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-607.
23. Amon U, Amon S, Gibbs BF: In vitro studies with fexofenadine, a new nonsedating histamine H1 receptor antagonist, on isolated human basophils. Inflamm Res 2000;49(suppl 1):S13-S14.
24. Vena GA, Cassano N, Filieri M, Filotico R, D'Argento V, Coviello C: Fexofenadine in chronic idiopathic urticaria: a clinical and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2002;15:217-224.
25. Akagi M, Mio M, Miyoshi K, Tasaka K: Anti-allergic effects of terfenadine on immediate type hypersensitivity reactions. Immunopharmacol Immunotoxicol 1987;9:257-279.
26. Suzuki K, Sakairi T, Shakuto S, Yaguchi M, Atai H, Nishiyama Y: Inhibitory effects of fexofenadine hydrochloride (Allegra®). 1. Inhibitory effects on the various allergy reactions. The 51st General Convention of the Japanese Society of Allergology, Fukuoka, 2001.
27. Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A: Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002;110:85-95.
28. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J: Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:927-933.
29. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW: Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001;56:1068-1070.
30. Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ: A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:126-132.
31. Wilson AM, Haggart K, Sims EJ, Lipworth BJ: Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-1509.
32. Allocco FT, Votypka V, deTineo M, Naclerio RM, Baroody FM: Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol 2002;89:578-584.
33. Miyabe S, Koizuka I, Ochi K, Tanaka K, Kuroda H, Takatsu M, Kinoshita H, Sugiyama Y: Effect of fexofenadine hydrochloride on cedar pollinosis. Auris Nasus Larynx 2003;30(suppl):S61-S68.
34. Skoner DP, Asman B, Fireman P: Effects of chlorpheniramine on airway physiology and symptoms during natural pollen exposure. Am J Rhinol 1994;8:43-48.
35. Numata T, Konno A, Yamakoshi T, Hanazawa T, Terada N, Nagata H: Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-473.
36. Piatti G, Ceriotti L, Cavallaro G, Ambrosetti U, Mantovani M, Pistone A, Centanni S: Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 2003;47:541-547.
37. Murata Y, Sugimoto O: Zafirlukast (Accolate): a review of its pharmacological and clinical profile (in Japanese; English abstract). Nippon Yakurigaku Zasshi 2002;119:247-258.
38. Summary of AstraZeneca's Japanese New Drug Application dossier for Accolate (in Japanese), 2000;294. http://www.jpec.or.jp/contents/c01/link.html
39. Shirasaki H, Asakura K, Kojima T, Sohma S, Kataura A: The roles of histamine, leukotriene C4 and bradykinin on nasal vascular permeability in experimental nasal allergy of guinea pigs. Rhinology 1992;30:41-48.
40. Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S: Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. Jpn J Pharmacol 2001;86:170-182.
41. Okuda M, Watase T, Mezawa A, Liu CM: The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-540.
42. Brown MS, Peters SP, Adkinson NF Jr, Proud D, Kagey-Sobotka A, Norman PS, Lichtenstein LM, Naclerio RM: Arachidonic acid metabolites during nasal challenge. Arch Otolaryngol Head Neck Surg 1987;113:179-183.
43. Narita S, Asakura K, Shirasaki H, Kojima T, Kataura A: Studies on thromboxane B2 level in nasal lavage fluid after antigen challenge in patients with allergic rhinitis and guinea pig models (in Japanese; English abstract). Arerugi 1995;44:1159-1166.
44. Terada N, Yamakoshi T, Hasegawa M, Tanikawa H, Maesako K, Ishikawa K, Konno A: The effect of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis. Acta Otolaryngol 1998;537(suppl):32-37.
45. Motobayashi Y, Imagawa W, Saida K: Ramatroban (Baynas): a review of its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 2001;118:397-402.
46. Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M, Arita H: Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001;298:411-419.
47. Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW: The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther 1998;284:83-88.
48. Imai A, Nabe T, Mizutani N, Sakurai H, Takenaka H, Kohno S: Involvement of nitric oxide in pollen-induced biphasic nasal blockage in sensitised guinea pigs. Eur J Pharmacol 2001;423:63-70.
49. Kojima T, Asakura K: The study of chemical mediators in the patients with allergic rhinitis 2). Histamine, leukotriene and kinins in the nasal secretion during dual phase response (in Japanese, English abstract). Nippon Jibiinkoka Gakkai Kaiho 1991;94:366-376.
50. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, Bacon KB: An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 2003;305:347-352.